financetom
Business
financetom
/
Business
/
Ulta Beauty Remains Poised to Meet 2025 Targets Despite Hurdles, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ulta Beauty Remains Poised to Meet 2025 Targets Despite Hurdles, Oppenheimer Says
May 26, 2025 10:57 AM

10:25 AM EDT, 05/20/2025 (MT Newswires) -- Ulta Beauty ( ULTA ) remains poised to meet 2025 targets despite a "more difficult" landscape, Oppenheimer said Tuesday in a report.

The company on May 29 probably will report fiscal Q1 results in line with market expectations and reiterate full-year guidance, Oppenheimer said in an earnings preview.

"We continue to see solid in-store execution and a rational promotional backdrop," Oppenheimer said. "We are encouraged by the strategic direction" under Kecia Steelman, the new chief executive officer, the report said.

Execution of key digital priorities is a focus in the coming quarters, aiming at sustaining a competitive edge against Amazon.com (AMZN), Walmart (WMT)] and other rivals, the report said.

Oppenheimer boosted its price target on Ulta Beauty ( ULTA ) stock to $465 from $435 and maintained its outperform rating.

Shares of the company rose 2.4% in recent trading Tuesday.

Price: 420.09, Change: +10.00, Percent Change: +2.44

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Esperion Therapeutics Says Bempedoic Acid Receives Multiple Class 1 Recommendations
Esperion Therapeutics Says Bempedoic Acid Receives Multiple Class 1 Recommendations
Mar 16, 2026
07:16 AM EDT, 03/16/2026 (MT Newswires) -- Esperion Therapeutics ( ESPR ) said Monday its cholesterol lowering therapy bempedoic acid received multiple Class 1 recommendations in the 2026 American College of Cardiology/American Heart Association multisociety guideline for the management of dyslipidemia. The company said the guideline provides the strongest endorsement for bempedoic acid in patients with statin intolerance, and in...
Helmerich & Payne CFO Kevin Vann to Retire; Todd Scruggs Named Successor
Helmerich & Payne CFO Kevin Vann to Retire; Todd Scruggs Named Successor
Mar 16, 2026
07:15 AM EDT, 03/16/2026 (MT Newswires) -- Helmerich & Payne (HP) said Monday that Chief Financial Officer Kevin Vann will retire on June 30. Todd Scruggs, vice president of corporate finance and treasury, was named Vann's successor, effective July 1, the company said. Vann will continue serving as a senior adviser through Dec. 31, Helmerich & Payne added. ...
Form 8.3
Form 8.3
Mar 16, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3
Form 8.3
Mar 16, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee...
Copyright 2023-2026 - www.financetom.com All Rights Reserved